Benson Yu, MD
Internal Medicine · Fairfax, VANPI 1518951557
Payments from drug & device makers
Across 370 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Gilead$1K
- Novo Nordisk$869
- AstraZeneca$715
- Bayer$637
- Pfizer$449
- plus $4K from 32 others
What the payments were for
- Food & beverage$8,74898%
- Education$1392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 47 | $1,141 |
| Gilead | 43 | $1,049 |
| Novo Nordisk | 44 | $869 |
| AstraZeneca(2 entities) | 25 | $715 |
| Bayer | 22 | $637 |
| Pfizer | 15 | $449 |
| Amarin Pharma, Inc. | 18 | $377 |
| Lilly USA, LLC | 11 | $351 |
| Phathom Pharmaceuticals, Inc. | 7 | $337 |
| Evoke Pharma, Inc. | 12 | $322 |
| AbbVie(2 entities) | 14 | $279 |
| Sumitomo Pharma America, Inc. | 13 | $254 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $231 |
| Johnson & Johnson | 6 | $206 |
| GSK | 10 | $189 |
| Otsuka America Pharmaceutical, Inc. | 10 | $187 |
| Currax Pharmaceuticals LLC | 10 | $178 |
| Boehringer Ingelheim | 6 | $154 |
| Exactech, Inc. | 1 | $139 |
| Astellas Pharma US Inc | 8 | $133 |
| Amneal Pharmaceuticals LLC | 6 | $115 |
| Dexcom, Inc. | 4 | $82 |
| Exact Sciences | 3 | $54 |
| Redhill Biopharma Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Abbott | 2 | $46 |
| Travere Therapeutics, Inc. | 3 | $43 |
| Eisai Inc. | 2 | $43 |
| Sanofi Pasteur Inc. | 2 | $41 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Merck | 1 | $24 |
| Genentech USA, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,887 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 80 | $95,054 |
| ProliaDenosumab | 46 | $81,741 |
| VascepaIcosapent Ethyl | 119 | $79,701 |
| FarxigaDapagliflozin Propanediol | 51 | $74,784 |
| JanuviaSitagliptin Phosphate | 24 | $42,440 |
| OzempicSemaglutide | 36 | $42,422 |
| VemlidyTenofovir Alafenamide | 27 | $38,530 |
| EliquisApixaban | 17 | $29,859 |
| TrulicityDulaglutide | 15 | $22,370 |
| JardianceEmpagliflozin | 14 | $19,969 |
| MyrbetriqMirabegron | 19 | $15,063 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,784 |
| Rosuvastatin Calcium | 791 | $9,215 |
| Lidocaine | 49 | $7,777 |
| SynthroidLevothyroxine Sodium | 43 | $6,524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Synthroid | $279 | $101,578123 claims |
| AmgenProlia | $1,141 | $81,74146 claims |
| AstraZenecaFarxiga | $715 | $74,78451 claims |
| MerckJanuvia | $24 | $42,44024 claims |
| Novo NordiskOzempic | $869 | $42,42236 claims |
| GileadVemlidy | $1,049 | $38,53027 claims |
| PfizerEliquis | $449 | $29,85917 claims |
| Lilly USA, LLCTrulicity | $351 | $22,37015 claims |
| Boehringer IngelheimJardiance | $154 | $19,96914 claims |
| Astellas Pharma US IncMyrbetriq | $133 | $15,06319 claims |
| GSKTrelegy Ellipta | $189 | $9,78415 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $115 | $1,144120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Fairfax
- Stanley StrickbergerFairfax$93K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.